Guardant Health Inc.: Shield Added to ACS Guidelines / Camizestrant PDUFA Extended

Research evidence excerpt

Guardant Health Inc.: Shield Added to ACS Guidelines / Camizestrant PDUFA Extended

Update

May 27, 2026 01:46 PM GMT

Morgan Stanley & Co. LLCMGuardant Health Inc. | North America Kallum L Titchmarsh

Equity Analyst

Shield Added to ACS Guidelines Kallum.Titchmarsh@morganstanley.comJakob Dodd +1 212 761-2351

Research Associate

Jakob.Dodd@morganstanley.com +1 212 761-0797

/ Camizestrant PDUFA Extended Jason Lai

Jason.Lai@morganstanley.com +1 212 761-4848

Key Takeaways

Guardant Health Inc. (GH.O, GH US)

Shield now recommended by ACS as a CRC screening modality. Life Science Tools & Diagnostics | United States of

America

Inclusion in guidelines was mostly expected but still a meaningful positive for GH.

Stock Rating Overweight

Separately, FDA approval of camizestrant (with G360 surveillance) looks more Industry View In-Line

Price target $130.00

likely on PDUFA extension. Shr price, close (May 26, 2026) $119.85

Mkt cap, curr (mm) $16,648

52-Week Range $121.01-37.73

What happened? Earlier today, the American Cancer Society (ACS) published new

guidelines for colorectal cancer (CRC) screening, now recommending GH's Shield

blood test for average-risk US adults age 45+ who decline or do not complete the

preferred screening tests (stool-based tests or colonoscopy). We think this update

to CRC screening guidelines marks the first meaningful change since 2018 when the

recommended age for average-risk adults to begin screening was decreased to 45

from 50.

What does it mean for GH? We view the updated guidelines as a significant –

though mostly expected – win for GH. While we had heard Shield's inclusion was

imminent for some time, we think the news today is still a relief for investors given

some increasing doubts we had fielded recently. Depending on the pace of expanded